GIMAP2

Across TCGA pan-cancer cohorts, GIMAP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GIMAP2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GIMAP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GIMAP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

LSCC, GBM, and PDAC are the cancer types where GIMAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.637	1.000	<.001	28	view →
GBM	DFS	Median	All	0.639	0.868	<.001	13	view →
PDAC	OS	Quartile	All	0.564	0.300	.021	10	view →
LUAD	DFS	Quartile	III,IV	0.875	0.334	.008	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GIMAP2–LSCC (OS)

Open the LSCC breakdown →